Stephen Willey
Stock Analyst at Stifel
(3.94)
# 585
Out of 5,147 analysts
131
Total ratings
45.26%
Success rate
13.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACLX Arcellx | Downgrades: Hold | $127 → $115 | $113.79 | +1.06% | 2 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $125 → $110 | $66.62 | +65.12% | 2 | Feb 17, 2026 | |
| INCY Incyte | Maintains: Buy | $119 → $120 | $101.27 | +18.50% | 8 | Feb 11, 2026 | |
| EXEL Exelixis | Maintains: Hold | $43 → $44 | $44.06 | -0.14% | 20 | Feb 11, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $33 → $35 | $15.97 | +119.16% | 6 | Jan 29, 2026 | |
| ZYME Zymeworks | Maintains: Buy | $30 → $40 | $23.29 | +71.75% | 7 | Nov 19, 2025 | |
| CELC Celcuity | Maintains: Buy | $68 → $115 | $111.71 | +2.95% | 2 | Nov 13, 2025 | |
| NKTX Nkarta | Maintains: Buy | $12 → $11 | $2.70 | +307.41% | 5 | Nov 11, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $30 → $9 | $3.44 | +161.63% | 3 | Aug 29, 2025 | |
| INSM Insmed | Maintains: Buy | $121 → $145 | $149.33 | -2.90% | 8 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.61 | +93.91% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $12.09 | +131.60% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $5 | $1.99 | +151.26% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $20 | $4.52 | +342.48% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $15.44 | +547.67% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.68 | +138.10% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $16.78 | +180.10% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $0.28 | +1,328.06% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $1.81 | +120.99% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $43.23 | +43.42% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.65 | +59.29% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.72 | +597.67% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.81 | +15,811.60% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.17 | +867.74% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $1.47 | +172.11% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $332.92 | -63.05% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $81.15 | -42.08% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $61.73 | +76.58% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $22.96 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $7.58 | +203.43% | 5 | Feb 7, 2018 |
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $127 → $115
Current: $113.79
Upside: +1.06%
Disc Medicine
Feb 17, 2026
Maintains: Buy
Price Target: $125 → $110
Current: $66.62
Upside: +65.12%
Incyte
Feb 11, 2026
Maintains: Buy
Price Target: $119 → $120
Current: $101.27
Upside: +18.50%
Exelixis
Feb 11, 2026
Maintains: Hold
Price Target: $43 → $44
Current: $44.06
Upside: -0.14%
Nurix Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $15.97
Upside: +119.16%
Zymeworks
Nov 19, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $23.29
Upside: +71.75%
Celcuity
Nov 13, 2025
Maintains: Buy
Price Target: $68 → $115
Current: $111.71
Upside: +2.95%
Nkarta
Nov 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.70
Upside: +307.41%
X4 Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $30 → $9
Current: $3.44
Upside: +161.63%
Insmed
Aug 14, 2025
Maintains: Buy
Price Target: $121 → $145
Current: $149.33
Upside: -2.90%
Aug 8, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.61
Upside: +93.91%
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $12.09
Upside: +131.60%
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $1.99
Upside: +151.26%
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $4.52
Upside: +342.48%
Mar 21, 2025
Maintains: Buy
Price Target: $240 → $100
Current: $15.44
Upside: +547.67%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.68
Upside: +138.10%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $16.78
Upside: +180.10%
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $0.28
Upside: +1,328.06%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $1.81
Upside: +120.99%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $43.23
Upside: +43.42%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $5.65
Upside: +59.29%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $1.72
Upside: +597.67%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.81
Upside: +15,811.60%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.17
Upside: +867.74%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $1.47
Upside: +172.11%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $332.92
Upside: -63.05%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $81.15
Upside: -42.08%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $61.73
Upside: +76.58%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $22.96
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $7.58
Upside: +203.43%